The atypical cannabinoid O-1602: Targets, actions, and the central nervous system

Central Nervous System Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 233-239

  Ashton, John C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Abnormal Cannabidiol; Cannabidiol; Cannabinoid; GPR18; gPR55; Inflammation; Microglia; O 1602

Indexed keywords

11 HYDROXYDRONABINOL; ABNORMAL CANNABIDIOL; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CANNABIDIOL; CANNABIDIOL DERIVATIVE; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 18; G PROTEIN COUPLED RECEPTOR 55; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; O 1602; O 1821; O 1918; SEROTONIN 1A RECEPTOR; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

ALLODYNIA; BONE MASS; CENTRAL NERVOUS SYSTEM; COLITIS; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFECT; DRUG TARGETING; HUMAN; ILEUS; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; KNEE ARTHRITIS; KNEE PAIN; KNOCKOUT MOUSE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NEUROPATHIC PAIN; NONHUMAN; OBESITY; RECEPTOR AFFINITY; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; CYCLOHEXANES; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; RESORCINOLS;

EID: 84866709501     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/187152412802430156     Document Type: Review

References (62)

1. Devane, W. A.; Dysarz, F. A., 3rd; Johnson, M. R.; Melvin, L. S.; Howlett, A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, 34 (5), 605-13.
2. Izzo, A. A.; Mascolo, N.; Capasso, F. The gastrointestinal pharmacology of cannabinoids. Curr. Opin. Pharmacol., 2001, 1 (6), 597-603
3. Njie, Y. F.; Kumar, A.; Qiao, Z.; Zhong, L.; Song, Z. H. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. Invest Ophthalmol. Vis. Sci., 2006, 47 (5), 1999-2005
4. Park, B.; Gibbons, H. M.; Mitchell, M. D.; Glass, M. Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. Placenta, 2003, 24 (10), 990-5.
5. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365 (6441), 61-5.
6. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232 (1), 54-61.
7. Cabral, G.; Marciano-Cabral, F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol., 2005, 78 (6), 1192-7.
8. Atwood, B. K.; Mackie, K., CB2: a cannabinoid receptor with an identity crisis. Br. J. Pharmacol., 2010, 160 (3), 467-79.
9. Scotter, E.; Graham, S.; Glass, M., Cannabinoid Receptor Signal Transduction Pathways. In Cannabinoids: Structure and Function, Reggio, P., Ed. Humana Press: 2006.
10. Anavi-Goffer, S.; Baillie, G.; Irving, A. J.; Gertsch, J.; Greig, I. R.; Pertwee, R. G.; Ross, R. A. Modulation of L-alphalysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. J. Biol. Chem., 2012, 287 (1), 91-104.
11. van der Stelt, M.; Di Marzo, V. Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins lipid mediat., 2005, 77 (1-4), 111-22.
12. Michoulam, R.; Shvo, Y., Hashish. I. The structure of cannabidiol. Tetrahedron, 1963, 19 (12), 2073-8.
13. Scuderi, C.; Filippis, D. D.; Iuvone, T.; Blasio, A.; Steardo, A.; Esposito, G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytother. Res., 2009, 23 (5), 597-602.
14. Bisogno, T.; Hanus, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, D. E.; Brandi, I.; Moriello, A. S.; Davis, J. B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 2001, 134 (4), 845-52.
15. Mechoulam, R.; Peters, M.; Murillo-Rodriguez, E.; Hanus, L. O. Cannabidiol--recent advances. Chem. Biodivers., 2007, 4 (8), 1678-92.
16. Adams, M. D.; Earnhardt, J. T.; Martin, B. R.; Harris, L. S.; Dewey, W. L.; Razdan, R. K. A cannabinoid with cardiovascular activity but no overt behavioral effects. Experientia, 1977, 33 (9), 1204-5.
17. Jarai, Z.; Wagner, J. A.; Varga, K.; Lake, K. D.; Compton, D. R.; Martin, B. R.; Zimmer, A. M.; Bonner, T. I.; Buckley, N. E.; Mezey, E.; Razdan, R. K.; Zimmer, A.; Kunos, G. Cannabinoidinduced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A., 1999, 96 (24), 14136-41.
18. Franklin, A.; Stella, N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormalcannabidiol-sensitive receptors. Eur. J. Pharmacol., 2003, 474 (2-3), 195-8.
19. Walter, L.; Franklin, A.; Witting, A.; Wade, C.; Xie, Y.; Kunos, G.; Mackie, K.; Stella, N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci., 2003, 23 (4), 1398-405.
20. Su, J. Y.; Vo, A. C. 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling. Eur. J. Pharmacol., 2007, 559 (2-3), 189-95.
21. Schuelert, N.; McDougall, J. J. The abnormal cannabidiol analogue O-1602 reduces nociception in a rat model of acute arthritis via the putative cannabinoid receptor GPR55. Neurosci. Lett., 2011, 500 (1), 72-6.
22. Offertaler, L.; Mo, F. M.; Batkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B. R.; Bukoski, R. D.; Kunos, G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol., 2003, 63 (3), 699-705.
23. McHugh, D.; Hu, S. S. J.; Rimmerman, N.; Juknat, A.; Vogel, Z.; Walker, J. M.; Bradshaw, H. B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci., 2010, 11 (20346144), 44-44.
24. Johns, D. G.; Behm, D. J.; Walker, D. J.; Ao, Z.; Shapland, E. M.; Daniels, D. A.; Riddick, M.; Dowell, S.; Staton, P. C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T. L.; Brown, A. J.; Morrison, A. D.; Douglas, S. A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol., 2007, 152 (5), 825-31.
25. Ashton, J. C.; Wright, J. L.; McPartland, J. M.; Tyndall, J. D. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Curr. Med. Chem., 2008, 15 (14), 1428-43.
26. Kreutz, S.; Koch, M.; Bottger, C.; Ghadban, C.; Korf, H. W.; Dehghani, F. 2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells. Glia, 2009, 57 (3), 286-94.
27. McHugh, D.; Hu, S. S.; Rimmerman, N.; Juknat, A.; Vogel, Z.; Walker, J. M.; Bradshaw, H. B. N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci., 2010, 11, 44.
28. Samuelson, L. C.; Swanberg, L. J.; Gantz, I. Mapping of the novel G protein-coupled receptor Gpr18 to distal mouse chromosome 14. Mamm. Genome, 1996, 7 (12), 920-1.
29. Gantz, I.; Muraoka, A.; Yang, Y. K.; Samuelson, L. C.; Zimmerman, E. M.; Cook, H.; Yamada, T. Cloning and chromosomal localization of a gene (GPR18) encoding a novel seven transmembrane receptor highly expressed in spleen and testis. Genomics, 1997, 42 (3), 462-6.
30. Kohno, M.; Hasegawa, H.; Inoue, A.; Muraoka, M.; Miyazaki, T.; Oka, K.; Yasukawa, M. Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. Biochem. Biophys. Res. Commun., 2006, 347 (3), 827-32.
31. Rimmerman, N.; Bradshaw, H. B.; Hughes, H. V.; Chen, J. S.; Hu, S. S.; McHugh, D.; Vefring, E.; Jahnsen, J. A.; Thompson, E. L.; Masuda, K.; Cravatt, B. F.; Burstein, S.; Vasko, M. R.; Prieto, A. L.; O'Dell, D. K.; Walker, J. M. N-palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons. Mol. Pharmacol., 2008, 74 (1), 213-24.
32. Burstein, S. H.; McQuain, C. A.; Ross, A. H.; Salmonsen, R. A.; Zurier, R. E. Resolution of inflammation by Narachidonoylglycine. J. Cell Biochem., 2011, 112 (11), 3227-33.
33. Takenouchi, R.; Inoue, K.; Kambe, Y.; Miyata, A. N-arachidonoyl glycine induces macrophage apoptosis via GPR18. Biochem. Biophys. Res. Commun., 2012, 418 (2), 366-71.
34. Lauckner, J. E.; Jensen, J. B.; Chen, H. Y.; Lu, H. C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A., 2008, 105 (7), 2699-704
35. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362 (4), 928-34
36. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152 (7), 1092-101
37. Waldeck-Weiermair, M.; Zoratti, C.; Osibow, K.; Balenga, N.; Goessnitzer, E.; Waldhoer, M.; Malli, R.; Graier, W. F. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci., 2008, 121 (Pt 10), 1704-17.
38. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem., 2009, 145 (1), 13-20.
39. Nevalainen, T.; Irving, A. J. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity? Curr. Top Med. Chem., 2010, 10 (8), 799-813.
40. Schicho, R.; Bashashati, M.; Bawa, M.; McHugh, D.; Saur, D.; Hu, H. M.; Zimmer, A.; Lutz, B.; Mackie, K.; Bradshaw, H. B.; McCafferty, D. M.; Sharkey, K. A.; Storr, M. The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm. Bowel. Dis., 2011, 17 (8), 1651-64.
41. Lin, X. H.; Yuece, B.; Li, Y. Y.; Feng, Y. J.; Feng, J. Y.; Yu, L. Y.; Li, K.; Li, Y. N.; Storr, M. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol. Motil, 2011, 23 (9), 862-e342.
42. Breen, C.; Brownjohn, P. W.; Ashton, J. C. The atypical cannabinoid O-1602 increases hind paw sensitisation in the chronic constriction injury model of neuropathic pain. Neurosci. Lett., 2012, 508 (2), 119-22.
43. Staton, P. C.; Hatcher, J. P.; Walker, D. J.; Morrison, A. D.; Shapland, E. M.; Hughes, J. P.; Chong, E.; Mander, P. K.; Green, P. J.; Billinton, A.; Fulleylove, M.; Lancaster, H. C.; Smith, J. C.; Bailey, L. T.; Wise, A.; Brown, A. J.; Richardson, J. C.; Chessell, I. P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain, 2008, 139 (1), 225-36.
44. Lauckner, J.; Jensen, J.; Chen, H.; Lu, H.; Hille, B.; Mackie, K., GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Nat. Acad. Sci., 2008, 105 (7), 2699.
45. Neumann, S.; Doubell, T.; Leslie, T.; Woolf, C. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature, 1996, 384 (6607), 360-364.
46. Diaz-Arteaga, A.; Vazquez, M. J.; Vazquez-Martinez, R.; Pulido, M. R.; Suarez, J.; Velasquez, D. A.; Lopez, M.; Ross, R. A.; de Fonseca, F. R.; Bermudez-Silva, F. J.; Malagon, M. M.; Dieguez, C.; Nogueiras, R. The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes. Metab., 2012, 14 (3), 234-43.
47. Romero-Zerbo, S. Y.; Rafacho, A.; Diaz-Arteaga, A.; Suarez, J.; Quesada, I.; Imbernon, M.; Ross, R. A.; Dieguez, C.; Rodriguez de Fonseca, F.; Nogueiras, R.; Nadal, A.; Bermudez-Silva, F. J. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J. Endocrinol., 2011, 211 (2), 177-85.
48. Moreno-Navarrete, J. M.; Catalan, V.; Whyte, L.; Diaz-Arteaga, A.; Vazquez-Martinez, R.; Rotellar, F.; Guzman, R.; Gomez-Ambrosi, J.; Pulido, M. R.; Russell, W. R.; Imbernon, M.; Ross, R. A.; Malagon, M. M.; Dieguez, C.; Fernandez-Real, J. M.; Fruhbeck, G.; Nogueiras, R. The L-alpha-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes, 2012, 61 (2), 281-91.
49. Bab, I.; Ofek, O.; Tam, J.; Rehnelt, J.; Zimmer, A. Endocannabinoids and the regulation of bone metabolism. J. Neuroendocrinol, 2008, 20 Suppl, 1, 69-74
50. Bab, I.; Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Br. J. Pharmacol., 2008, 153 (2), 182-8.
51. Whyte, L. S.; Ryberg, E.; Sims, N. A.; Ridge, S. A.; Mackie, K.; Greasley, P. J.; Ross, R. A.; Rogers, M. J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. U.S.A., 2009, 106 (38), 16511-6.
52. Pietr, M.; Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y. H.; Stella, N.; Vogel, Z.; Juknat, A. Differential changes in GPR55 during microglial cell activation. FEBS Lett., 2009, 583 (12), 2071-6.
53. Watkins, L. R.; Milligan, E. D.; Maier, S. F. Glial activation: a driving force for pathological pain. Trends Neurosci., 2001, 24 (8), 450-5.
54. Ashton, J. C.; Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol., 2007, 5 (2), 73-80.
55. Felderhoff-Mueser, U.; Schmidt, O. I.; Oberholzer, A.; Buhrer, C.; Stahel, P. F. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci., 2005, 28 (9), 487-93.
56. Owolabi, S. A.; Saab, C. Y. Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn. FEBS Lett., 2006, 580 (18), 4306-10.
57. Ashton, J. C. Synthetic cannabinoids as drugs of abuse. Curr. Drug Abuse Rev., 2012, 5(2), 158-168.
58. Meulendyke, K. A.; Pletnikov, M. V.; Engle, E. L.; Tarwater, P. M.; Graham, D. R.; Zink, M. C. Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIVassociated neurological disease. J. Neuroimmune Pharmacol., 2011
59. Tang, M.; Alexander, H.; Clark, R. S.; Kochanek, P. M.; Kagan, V. E.; Bayir, H. Minocycline reduces neuronal death and attenuates microglial response after pediatric asphyxial cardiac arrest. J. Cereb. Blood Flow Metab., 2010, 30 (1), 119-29
60. Noble, W.; Garwood, C. J.; Hanger, D. P. Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion, 2009, 3 (2), 78-83.
61. McPartland, J. M.; Glass, M.; Pertwee, R. G. Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br. J. Pharmacol., 2007, 152 (5), 583-93.
62. McHugh, D.; Page, J.; Dunn, E.; Bradshaw, H. B. Delta(9)-Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br. J. Pharmacol., 2012, 165 (8), 2414-24.